Evidence map›Paper›PMID 17661091›Full record

ArticlePediatric nephrology (Berlin, Germany)2007

Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.

Gian Marco Ghiggeri, Luca Musante, Giovanni Candiano, Maurizio Bruschi, Laura Santucci, Giancarlo Barbano, Antonella Trivelli, Lucia Rivabella, Rosanna Gusmano, Francesco Perfumo

Registry-linked trialAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04494438 (Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04494438 phase3completednot on this mapstarted 2013, after this paper: background citation

Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome

TypeinterventionalSponsorIstituto Giannina GasliniRan2013 to 2016Enrolled30ConditionsIdiopathic Nephrotic SyndromeArmsRituximab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Gian Marco GhiggeriDepartment of Nephrology, G. Gaslini Children's Hospital, Genoa, Italy. labnefro@ospedale-gaslini.ge.it
Luca Musante
Giovanni Candiano
Maurizio Bruschi
Laura Santucci
Giancarlo Barbano
Antonella Trivelli
Lucia Rivabella
Rosanna Gusmano
Francesco Perfumo
Istituto Giannina Gaslini · ITChildren's Research Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a child presenting with oligoclonal plasma IgM (1.2 g%) and nephrotic syndrome with focal segmental glomerulosclerosis. Oligoclonality was demonstrated by the analysis of the complementary determining region 3 (CDR 3) on immunoglobulin heavy chains and by two dimensional electrophoresis and Western blot analysis that showed the bulk of isoforms having a cationic muU chain compared with the normal homologue (pI 7.5 vs 6.5). Urinary light chains were absent, and bone marrow aspirate was normal. Usual therapies for nephrotic syndrome with steroids and cyclosporin were useless. At the age of 9 years the patient was treated with plasmapheresis plus cyclophosphamide (2 mg/kg per day for 60 days), which temporarily reduced plasma IgM, and proteinuria was normal for 3 years. After this period, due to new recurrence of nephrotic syndrome, the patient received a cycle with anti-CD20 antibodies (500 mg/m(2) every week for a month) associated with a cycle of plasmapheresis that normalized proteinuria again, and, after 3 years, the proteinuria is still in remission. This is the first case of nephrotic syndrome associated with oligoclonal plasma IgM and mesangial IgM deposits. Both cyclophosphamide and anti-CD20 antibodies associated with plasmapheresis induced, at different stages, stable and protracted remission of proteinuria without evident side effects. Long term efficacy and safety of the association are still to be determined.

Indexed as

PlasmapheresisAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedChildCombined Modality TherapyCyclophosphamideGlomerulonephritisGlomerulosclerosis, Focal SegmentalHumansImmunologic FactorsImmunosuppressive AgentsMaleNephrotic SyndromeOligoclonal BandsProteinuriaRemission InductionAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedCyclophosphamideImmunologic FactorsImmunosuppressive AgentsOligoclonal BandsRituximab

Identifiers

PMID17661091
OpenAlexW1992764385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.